Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But if they don’t file the Q1 in timely fashion, it will be back to the Yield sign again. THe Dr needs to start being ON TIME with updates and filings.
WHAT HAPPEND HERE TODAY???LOL.IT GOT CRAZY WHEN THE BIG BIDS MOVED UP.LMAOOOO.THEY SAY IF YOU DO NOT WANT TO GET FD,DON;T F WITH MY TRADES.LET;S SEE WHAT HAPPENS NEXT WEEK MY LIONS.
looking for $1-$5 in few months.
The below e-mail reply from ViaDerma >>>>>
Hi John,
Thank you for reaching out to us. When the current formula is rubbed into the skin it shows no color. Our previous version used the active ingredient "Tetracycline" which was dark yellow/brown and stained the skin and clothes. Our new version "Vitastem Ultra" uses Bacitracin as the active ingredient which is clear. That is what the ultra clear formula is referring to specifically. The slight yellow tint is from the Vitamin C in the formula but when rubbed into the skin will not stain. However, we do appreciate your feedback and would like to offer you a FREE bottle to try to make up for your stained shirt. In the future, if you make sure to rub the formula into the skin and let it dry it should not stain your clothes. But if you feel it may be an issue you can use a Band-Aid or bandage over the area to make sure not to stain your shirt.
Your new FREE bottle of Vitastem Ultra will be shipped out early next week.
Thank you,
Taylor Renee
Customer Service Manager
ViaDerma Pharma
Phone: 800-585-8685
Email: info@ViaDerma.com
VitaStem is the only horse here I'm betting.
Beninvest Well said I'm not here 4 chump change
They may have got some news from FDA about Nupelo alo.
I’m not here for a new car, I want a new house! Let’s go to da moon!
Great product potentially international deals.
sure, just hold , you will be rewarded big time
At the close VDRM,,,17,487,128,, Last at 14,,,, UP 56.42%. Was close did trade at .015
How about Beer & cookies?
Monday get ready , bring chocolate cookies
I do believe the volume is up. :)
Need bigger volume to start triggering boards…
Monday huge day, get up early to watch announcement
I know it's a gamble but it's looking much better
All is done except bringing in the $$$$$GO VDRM
We are now ready to sell with huge revenew
We have come a long ways sense Dubai contract
WHAT IF (in the next two to four weeks):
> 2023 Annual Report, is issued with Attorney Letter and Company Profile update as required to restore Current Status; and
> Formal PR is issued regarding 2023 results and 2024 forecasts, including formal announcement of promised 1st overseas shipment and forecast of 2nd (or more) shipments.
Track record indicates otherwise, but, at least, there is a measure more plausibility today than there has been since Dubai contract fell through without explanation to shareholders.
Only Dr. O would keep selling @ these prices
Fingers crossed. We have enough of positive news to get us there. Bot sure if volume can sustain.
To the moon let’s go baby!!!!
Monday or later today, .0150
EXPERT MARKET YOU NEVER WANT TO FALL.=DEATH OF THE STOCK.LET;S HOPE HE FILES AND WE DO NOT FALL IN EXPERT MARKET.IF WE FALL IN EXPERT MARKET IS EXTREMELY HARD TO GO CURRENT AGAIN.
HERE ARE 5 STOCKS THAT HAVE FALLEN IN THE EXPERT MARKET IN THE LAST 12 MONTHS.
BRAV,GLCO.,SPSO,WSRC,MEDH.CHECK HISTORICAL PRICES ON THEM.NO VOLUMES.AND THEY TRADE IN THE TRIPLE ZERO AREA.
.0001 TO .0005.ONE OF THEM MEDH IS BEEN TRYING TO GET OUT OF THE EXPERT MARKET.THE OTC KEEPS ASKING FOR MORE INFO.BACK AND FORTH CRAP FOR A YEAR NOW.SO VDRM BETTER NOT FALL IN EXPERT MARKET.
thanks! great news.
A stock moves to Expert Market if Pink Limited requirements are not met. Ultra simplification is that such a move is usually and effectively a death knell for a stock. HOWEVER, it now seems to be negligible risk, with forecast issue of Annual Report by end of March. If desired, more information is in the following link.
https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/
buy in big block, thanks me on Monday
watch your language, its just a start, news pending
Please explain what expert market is?
Below are the deadlines for Annual Report relative to preventing move to Expert Market
** 16-month deadline is April 30, 2024
** 16-month plus 15-day grace period deadline is May 15, 2024
IR reported last week that Annual Report will be done by end of March, which seems credible with issue of 2nd and 3rd quarter.
Rah rah rah! Some one knows something rah rah rah!!
.03??? I think this can hit $10!!!!
195 countries 1 big contract very doable
does this go to the expert mkt if they don't get the yearly fins in by next week?
Finally 2 million plus on the bid at 102
Yes indeed, .07 with good contract min. But at least right now not sub penny again.
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74600
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |